NCT07088354Recruiting
Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy
Source: ClinicalTrials.gov · Last updated 28 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to develop and validate a deep learning model to predict pathological complete response (pCR) in patients with esophageal squamous cell carcinoma who have undergone neoadjuvant immunochemotherapy. Clinical, imaging, and pathological data from previously treated patients will be collected and analyzed. The model is expected to assist in predicting treatment outcomes and guide personalized therapeutic strategies.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 17 Jul 2025
- Start date
- 1 Mar 2025
- Primary completion date
- 1 Jun 2026
- Lead sponsor
- Tongji Hospital
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT07088354
What you commit to
- Study type: Observational
- Planned participants: 300
- From 1 Mar 2025 to the primary completion date, 1 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received other anti-tumor therapies before or during neoadjuvant chemo-immunotherapy.
Other illness
- Diagnosis of other malignancies.
Other
- Incomplete clinical data.
- Poor-quality CT imaging.
Who the study is looking for
- Pathologically confirmed esophageal squamous cell carcinoma (ESCC).
- Received at least one cycle of neoadjuvant chemotherapy combined with immunotherapy.
- Underwent contrast-enhanced chest CT before initiation of neoadjuvant treatment.
- Underwent contrast-enhanced chest CT after completion of neoadjuvant treatment and prior to surgery.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Coordinator of this site? Confirm its status | Wuhan | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.